Rapid-infusion rituximab in lymphoma treatment
Authors:
Open Access
- 1 December 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (6) , 1027-1028
Abstract
Rituximab® (MabThera; Rituxan Roche) is a chimeric human/murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell-surface antigen, CD20. Using the combination of CHOP-R leads to significant improvement in the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefits maintained during a 5-year follow-up [1].Keywords
This publication has 5 references indexed in Scilit:
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood, 2004
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002